scholarly journals Giant simple hepatic cyst with multiple elevated serum tumor markers: A case report

2020 ◽  
Vol 12 (12) ◽  
pp. 549-554
Author(s):  
Jia-Wei Zhang ◽  
Cheng Peng ◽  
Yan-Shuo Ye ◽  
Wei Li
Keyword(s):  
Case Report ◽  
Tumor Markers ◽  
Elevated Serum ◽  
Hepatic Cyst ◽  
Serum Tumor Markers ◽  
Simple Hepatic Cyst

Elevated CA 19-9 Levels in Mature Cystic Teratoma of the Ovary

2009 ◽  
Vol 24 (1) ◽  
pp. 52-56 ◽  
Author(s):  
Min Sun Kyung ◽  
Joong Sub Choi ◽  
Seung Hwa Hong ◽  
Hak Soon Kim
Keyword(s):  
Tumor Markers ◽  
Elevated Serum ◽  
Cystic Teratoma ◽  
Ovarian Torsion ◽  
Mature Cystic Teratoma ◽  
Ca 125 ◽  
Clinical Value ◽  
Blood Samples ◽  
Serum Tumor Markers

The purpose of this study was to evaluate the clinical value of serum tumor markers in patients with ovarian mature cystic teratoma (MCT). We retrospectively evaluated 163 women who underwent surgery for MCT of the ovary between March 2003 and August 2007 and who provided preoperative blood samples for the measurement of CA 19-9 and CA 125. The rates of elevated serum CA 19-9 and CA 125 levels were 31.9% (52/163) and 13.5% (22/163), respectively. The rate of ovarian torsion was 12.9% (21/163). There were significant differences between the elevated CA 19-9 group and the normal CA 19-9 group in the diameters of the tumors and the rates of ovarian torsion. Elevated serum CA 19-9 levels correlated with larger tumor diameters and higher torsion rates. CA 19-9 may be a useful tool for the diagnosis of ovarian MCT. Elevated CA 19-9 levels appear to correlate with larger tumor diameters and higher rates of ovarian torsion.

Phase II study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy in patients with muscle-invasive urothelial cancer (MI-UC): Pathologic and radiologic response, serum tumor markers, and DNA excision repair pathway biomarkers in relation to disease-free survival (DFS).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 4530-4530
Author(s):  
Angela Q. Qu ◽  
Susanna J. Jacobus ◽  
Sabina Signoretti ◽  
Edward C. Stack ◽  
Katherine Maragaret Krajewski ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Phase Ii ◽  
Residual Disease ◽  
Excision Repair ◽  
Elevated Serum ◽  
Disease Free Survival ◽  
Logrank Test ◽  
Tumor Biopsy ◽  
Serum Tumor Markers ◽  
Post Surgery

4530 Background: Neoadjuvant (NA) ddMVAC in patients (pts) with MI-UC is associated with significant pathologic response (PaR) and radiologic response (RaR). We examined the frequency of PaR and RaR as well as the level of serum and tissue biomarkers in correlation with DFS. Methods: Pts treated on phase II prospective study of NA ddMVAC (4 cycles) in MI-UC were evaluated for RaR (at least >50% decrease in the primary tumor and nodes after chemotherapy, with delayed enhancement of residual disease) and PaR (p<T1N0M0). Elevated serum tumor markers (CA125, C19-9 and ßHCG) at baseline and Day 1 of each cycle were documented. Expression level of baseline DNA ERCC1 protein in tumor biopsy tissues was determined by immunohistochemistry based on H-score <0.1 (negative) vs. >0.1 (positive). Fisher’s Exact test was used to evaluate association with response. Post-surgery DFS was estimated by the Kaplan-Meier method and compared between response and biomarker groups using the logrank test. Results: Of 39 pts (cT2:42%, cT3:42%, cT4:16%, and cN1:45%), 49% (90% CI 35-63) experienced PaR, and 62% (90% CI 47-75) achieved RaR after ddMVAC chemotherapy. Pts who achieved PaR experienced a DFS advantage, with 18-month DFS of 78% (95% CI 47-92) vs. 48% (95% CI 18-74) in those who did not (p=0.146). Those achieving RaR had a significantly longer DFS (p=0.006), with 18-month DFS of 87% (95% CI 57-97) vs. 29% (95% CI 5-60) in those who did not. Among 10 pts with any elevated serum tumor marker at baseline, only 2 pts showed normalization, both without a PaR. ERCC1(+) tumors were not associated with PaR, pT0 or RaR. DFS by ERCC1status was inconclusive due to limited sample size. 18-month DFS was 91% (95% CI 51-99) in ERCC1(+) tumors vs. 63% (95% CI 29-85) in ERCC1(-) tumors. Conclusions: ddMVAC achieves significant PaR and RaR in MI-UC pts that translates into a post-surgery DFS advantage. ERCC1(+) was not associated with response. More effective biomarkers of platinum response are needed to select pts most likely to benefit from NA therapy. Clinical trial information: NCT00808639.

Multicenter analysis of serum tumor markers, treatment patterns, and relapse in patients with testicular cancer in clinical stage IS.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 5052-5052
Author(s):  
Maximilian Peter Johannes Karl Brandt ◽  
Christian Guido Ruf ◽  
Klaus Peter Dieckmann ◽  
Isabella Syring ◽  
Christian Ruckes ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Half Life ◽  
Clinical Stage ◽  
Elevated Serum ◽  
Treatment Patterns ◽  
Relapse Free Survival ◽  
Chi Square ◽  
Free Survival ◽  
Serum Tumor Markers ◽  
Chi Square Test

5052 Background: Testicular germ cell tumors (TGCT) in clinical stage I (CSI) are tumors confined to the testis without evidence of metastasis. Around 50% of all TGCT patients present with elevated serum tumor markers (TM) such as alpha-feto protein (AFP), beta-humanochoriongonadotropin (ß-HCG) and lactate-dehydrogenase (LDH). After ablatio testis, TMs usually return to normal according to half-life kinetics, however, in clinical stage IS (CSIS) TMs remain elevated or increase after surgery. Follow-up data on CSIS is scarce and our study aims to assess clinical characteristics and oncologic outcomes in a large TGCT cohort. Methods: In this multicenter study we collected data from 5 tertiary referring hospitals in Germany, included patients with CSIS and evaluated TM levels, treatment and the primary outcome relapse-free survival. False CSIS was defined as documented CSIS but TMs that returned to normal after respective half-life kinetics. Differences between predefined groups (chemotherapy, TM, true/false CSIS) was analyzed with fisher’s exact and chi-square test. Results: Overall, 2616 patient data files were analyzed. Forty-three patients (1.6%) were documented as CSIS of which 27 (63%) were true and 16 (37%) false CSIS. Six (14%) had seminomas and 37 (86%) non-seminomas. In the true CSIS group AFP, ß-HCG, AFP plus ß-HCG and LDH were elevated in 13, 6, 3 and 2 cases. Four true CSIS patients received surveillance, 21 had 3x or 2x courses of BEP (bleomycin, etoposide and cisplatin) and 2 carboplatin. Within the false CSIS group, 2 patients were treated with surveillance, 10 received 3x BEP, one 3x PEI (cisplatin, etoposide and ifosfamid) and 3 had carboplatin. Chi-Square test revealed no difference between true or false CSIS classification in respect to application of chemotherapy (any chemotherapy, p = 0.83). Relapse-free survival after 5 and 10 years was 88.9% and 77.8%, respectively. Three patients in the true CSIS group relapsed (2 seminomas had carboplatin, 1 non-seminoma had surveillance). All relapses were treated with 3 courses of BEP with no documented death in the CSIS population. Conclusions: Overall, less than 2% of all TGCT were documented CSIS of which 37% were falsely classified. We report a high proportion of relapse-free survival in CSIS treated with surveillance or BEP with a high heterogeneity in treatment patterns. Correct classification of CSIS remains of critical importance to avoid toxicity for patients that could be safely treated with surveillance.

scholarly journals Giant simple hepatic cyst: a case report and review of relevant literature

2015 ◽  
Vol 15 (1) ◽  
pp. 293 ◽  
Author(s):  
M Asuquo ◽  
V Nwagbara ◽  
C Agbor ◽  
F Otobo ◽  
A Omotoso
Keyword(s):  
Case Report ◽  
Relevant Literature ◽  
Hepatic Cyst ◽  
Simple Hepatic Cyst

scholarly journals A Rare Complication of Simple Hepatic Cyst: Spontaneous Rupture, Case Report and Literature Review

2020 ◽  
Vol 28 (1) ◽  
pp. 5-8
Author(s):  
Yılmaz GÜLER ◽  
Serkan ŞENGÜL ◽  
Hasan ÇALIŞ ◽  
Özkan ÖZEN ◽  
Zülfikar KARABULUT
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Spontaneous Rupture ◽  
Rare Complication ◽  
Hepatic Cyst ◽  
Simple Hepatic Cyst

scholarly journals Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy?

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Patrick P. J. van der Veek ◽  
Wouter H. de Vos tot Nederveen Cappel ◽  
Alexandra M. J. Langers ◽  
Bart van Hoek
Keyword(s):  
Tumor Markers ◽  
Malignant Disease ◽  
Elevated Serum ◽  
Serum Levels ◽  
Stone Disease ◽  
High Serum ◽  
Response To Treatment ◽  
Serum Tumor Markers ◽  
Painless Jaundice ◽  
Very High

Serum tumor markers are useful to evaluate a cancer's response to treatment, for early detection of cancer relapse, and, in some cases, to diagnose malignancy. In this paper, we present two patients with significantly elevated serum tumor markerswithoutevidence of malignant disease. An 18-year-old patient suffering from autoimmune hepatitis had markedly increased alpha-fetoprotein (aFP) levels (2,002 μg/L; normal <10 ug/L). Extensive imaging showed no signs of hepatocellular carcinoma or other cancer, and treatment with Prednisone led to rapid normalization of both liver enzymes and aFP. The second patient, a 60-year-old female with painless jaundice due to biliary stone disease, had very high serum levels of CA19-9 (18,000 kU/L, normal <27 kU/L). Liver biochemistry and serum CA19-9 concentration decreased to almost normal values (45 kU/L) after biliary stenting. These cases demonstrate that serum tumor markers can be elevated in benign disease and are therefore not appropriate to diagnose cancer.

Sign in / Sign up

Export Citation Format

Share Document